Commentary: The multiple ways to tumor tolerance

Journal of Immunotherapy

Volumn 20, Issue 3, 1997, Pages 178-179

  Marincola, Francesco M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASM; NOTE;

HUMANS; IMMUNE TOLERANCE; NEOPLASMS;

EID: 0031131913     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199705000-00002     Document Type: Article

References (16)

1. van der Bruggen P, Traversari C, Chömez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
2. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med 1994;180:35-42.
3. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
4. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-19.
5. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nona peptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
6. Bakker AB, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cell in vitro. Cancer Res 1995;55:5330-4.
7. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
8. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-l/Melan A. Cancer J Sci Am (in press).
9. Salgaller ML, Marineóla FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res (in press).
10. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
11. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992;50:289-97.
12. Salgaller ML, Afshar A, Marineóla FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
13. Marineóla FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-l/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1996;19:266-77.
14. Ferrone S. Marineóla FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
15. Marineóla FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma associated antigens MART-1 and gp 100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996;19:192-205.
16. Chen Y, Stockert E, Tsang S, Coplan KE, Old LJ. Immunophenotyping of melanomas for tyrosinase: implication for vaccine development. Proc Natl Acad Sci USA 1995;92:8125-9.